Brown Advisory Inc. grew its position in AnaptysBio Inc (NASDAQ:ANAB) by 11.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,286 shares of the biotechnology company’s stock after purchasing an additional 12,172 shares during the quarter. Brown Advisory Inc. owned about 0.43% of AnaptysBio worth $11,402,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. boosted its holdings in AnaptysBio by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,342 shares of the biotechnology company’s stock valued at $5,992,000 after purchasing an additional 5,067 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in AnaptysBio in the second quarter valued at $211,000. BlackRock Inc. boosted its holdings in AnaptysBio by 2.9% in the second quarter. BlackRock Inc. now owns 1,464,624 shares of the biotechnology company’s stock valued at $104,046,000 after purchasing an additional 41,507 shares during the last quarter. Sei Investments Co. purchased a new stake in AnaptysBio in the second quarter valued at $780,000. Finally, Asymmetry Capital Management L.P. purchased a new stake in AnaptysBio in the second quarter valued at $2,893,000.
Several equities research analysts have commented on ANAB shares. Credit Suisse Group set a $147.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research lowered shares of AnaptysBio from a “hold” rating to a “sell” rating in a report on Friday, November 9th. Cantor Fitzgerald set a $140.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Friday, November 9th. JPMorgan Chase & Co. started coverage on shares of AnaptysBio in a report on Wednesday, November 21st. They issued an “overweight” rating and a $115.00 price target on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $121.00 price target on shares of AnaptysBio in a report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. AnaptysBio currently has an average rating of “Buy” and a consensus price target of $129.09.
Shares of AnaptysBio stock opened at $74.58 on Monday. AnaptysBio Inc has a fifty-two week low of $62.56 and a fifty-two week high of $134.00.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.05. The firm had revenue of $5.00 million during the quarter. As a group, analysts forecast that AnaptysBio Inc will post -2.79 EPS for the current fiscal year.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Featured Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.